AI
Wednesday, August 12, 2020 8:52:33 PM
$ADMS | #AdamasPharmaceuticals Upside Targets
Adamas Pharmaceuticals , Inc. engages in discovery and development of chrono-synchronous therapies for chronic neurologic disorders. Its products include GOCOVRI, ADS-5012, ADS-4101, and Namzaric. GOCOVRI is indicated for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy. ADS-5102 is a treatment for walking impairment in patients with multiple sclerosis. ADS-401 treats partial onset seizures in patients with epilepsy. Namzaric is a drug treatment for moderate to severe Alzheimer's disease. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.
Official InvestorsHub (IHUB) Profile for #TFMG | #theFinancialMarketingGroup:
#BullishCharts - https://investorshub.advfn.com/BullishChartscom-38003/
#TopMarketGainers - https://investorshub.advfn.com/Chart-Analysis-TopMarketGainerscom-36847/
Wytec Prepares for 1st AI Gunshot Detection Pilot • WYTC • Apr 4, 2025 7:09 AM
ConnectM Receives $1.60 Per Share Buyout Offer from its Three Largest Institutional Investors • CNTM • Apr 2, 2025 9:00 AM
Nightfood Holdings Completes Acquisition of Carryout Supplies, Deepening Vertical Integration in AI-Powered Hospitality Automation • NGTF • Apr 2, 2025 8:30 AM
Avant Technologies Partner, Ainnova, to Sponsor and Present at 2025 Healthcare Innovation Summit in Mexico City • AVAI • Apr 2, 2025 8:00 AM
Glidelogic Corp. Unveils ResearchMind - Pioneering AI-Driven Research Innovation for a Global Academic Community • GDLG • Apr 1, 2025 2:10 PM
Fifty 1 Labs, Inc. Celebrates Groundbreaking SpaceX, NASA, and ISS Yeast Experiment by Subsidiary Genetic Networks • FITY • Apr 1, 2025 9:30 AM
